๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil

โœ Scribed by Kazuya Tashiro; Toyohei Machida; Fujio Masuda; Yukihiko Ohishi

Publisher
Springer
Year
1983
Tongue
English
Weight
288 KB
Volume
11
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Combination chemotherapy for metastatic
Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate
โœ Ambrose Aboud; Aman U. Buzdar; Hwee-Yong Yap; Gabriel N. Hortobagyi; George R. B ๐Ÿ“‚ Article ๐Ÿ“… 1984 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 270 KB

Twenty-nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue. Of 24 evaluable patients, one achieved a complete remission and 17 had partial responses. The overall objective response r

5-Fluorouracil, adriamycin, and BCNU (FA
5-Fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer
โœ Massimo Lopez; Carlo Federico Perno; Luigi Lauro; Paola Papaldo ๐Ÿ“‚ Article ๐Ÿ“… 1984 ๐Ÿ› Springer ๐ŸŒ English โš– 406 KB

Thirty-two evaluable patients with advanced measurable gastric adenocarcinoma were treated with a combination of 5-fluorouracil, adriamycin, and BCNU (FAB). Two complete and fourteen partial responses were observed, with an overall response rate of 50%. The median duration of response was 10 months,

Combination chemotherapy with adriamycin
Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma
โœ Leroy M. Parker; C. Thomas Griffiths; Ronald A. Yankee; George P. Canellos; Rebe ๐Ÿ“‚ Article ๐Ÿ“… 1980 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 585 KB

Combination chemotherapy with Adriamycin-cyclophosphamide was employed after surgical treatment in 60 women with Stage 111-IV ovarian adenocarcinoma. Of 53 evaluable patients, objective response was noted in 34 of 41 (83%) without prior cytotoxic therapy but in only two of 12 (17%) who had failed a